The Mirasol® Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution

Blood Transfusion

Volumn 8, Issue 3, 2010, Pages 186-192

  Reikvam, Håkon ^a   Marschner, Susanne ^b   Apelseth, Torunn Oveland ^a   Goodrich, Ray ^b   Hervig, Tor ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b CaridianBCT Biotechnologies LLC   (United States)

Author keywords

Buffy coat platelet concentrates; Mirasol; Pathogen inactivation; Platelet storage

Indexed keywords

GLUCOSE; LACTATE DEHYDROGENASE; LACTIC ACID; PADGEM PROTEIN; RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ARTICLE; CELL VIABILITY; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; QUALITY CONTROL; TECHNOLOGY; THROMBOCYTE PRESERVATION; BIOSYNTHESIS; BLOOD BUFFY COAT; BLOOD STORAGE; CELL SURVIVAL; CYTOLOGY; EVALUATION; MEDICAL TECHNOLOGY; METABOLISM; METHODOLOGY; PH; SOLUTION AND SOLUBILITY; THROMBOCYTE; THROMBOCYTE COUNT; ULTRAVIOLET RADIATION;

BIOMEDICAL TECHNOLOGY; BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD PRESERVATION; CELL SURVIVAL; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; PHARMACEUTICAL SOLUTIONS; PLATELET COUNT; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 77954388476     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.0141-09     Document Type: Article

References (28)

1. Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med 1989; 321: 941-6.
2. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 112: 2617-26.
3. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289: 959-62.
4. Walther-Wenke G. Incidence of bacterial transmission and transfusion reactions by blood components. Clin Chem Lab Med 2008; 46: 919-25.
5. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
6. Wagner SJ, Skripchenko A, Myrup A, et al. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. Transfusion 2009; 49: 704-10.
7. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17. (Pubitemid 44354317)
8. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-82.
9. Cardo LJ, Salata J, Mendez J, et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131-7. (Pubitemid 350181574)
10. Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-92.
11. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22: 133-53.
12. Goodrich RP, Li J, Pieters H, et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-85.
13. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
14. Goodrich RP, Roberts T, Folléa G. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008; 48: 20A.
15. Gulliksson H. Additive solutions for the storage of platelets for transfusion. Transfus Med 2000; 10:257-64. (Pubitemid 32062541)
16. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
17. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911-9.
18. Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006; 46: 800-10.
19. Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007; 370: 427-38.
20. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22: 1-34.
21. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78 (Suppl 2): 211-5.
22. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90.
23. Li J, Xia Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion 2000; 40: 1320-9.
24. Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997; 37: 12-7. (Pubitemid 27068934)
25. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79: 206-14.
26. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004; 44: 320-9.
27. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-82.
28. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998; 38: 31-40.